Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 10:05:09 06/02/2026 pm IST			5-day change	1st Jan Change
6.148 ^EUR	+0.79%		-1.13%	+12.81%

03/02	Evotec Shares Surge Following Berenberg Buy Recommendation	DP
03/02	EVOTEC : Upgraded to Buy by Berenberg	ZD

Deutsche Bank Research raises Evotec to 'Hold' and target price to €7

Published on 04/24/2025 at 01:50 pm IST

dpa-AFX - Translated by Marketscreener - See original

EVOTEC SE

+0.79%

FRANKFURT (dpa-AFX Broker) - Deutsche Bank Research has upgraded Evotec from "Sell" to "Hold" and raised its price target from €4 to €7. Analyst Fynn Scherzler justified his new investment rating by stating that the drug developer's new targets for 2025 and beyond provide much-needed guidance. He also welcomed the new management team's plan to streamline the company's offering and set business targets carefully, the expert wrote in a study published on Thursday. /edh/la

Publication of the original study: April 24, 2025 / Time not specified in study / CEST

Initial release of the original study: April 24, 2025 / 7:54 a.m. / CEST

-----------------------

dpa-AFX Broker – trader news from dpa-AFX

-----------------------

Latest news about Evotec SE

03/02	Evotec Shares Surge Following Berenberg Buy Recommendation	DP
03/02	EVOTEC : Upgraded to Buy by Berenberg	ZD
03/02	Berenberg Initiates Evotec with 'Buy' Rating – Target Price Set at 10 Euros	DP
13/01	Evotec says Michael Kaufman holds 5.03% of total voting rights and instruments in Evotec	RE
08/01	Evotec Receives Gates Foundation Grant to Deploy AI in Optimizing Monoclonal Antibodies	MT
08/01	Evotec Remains in Demand on Tradegate – Funding Secured for Subsidiary	DP
07/01	Evotec Continues Upward Trend Following Amgen's Acquisition of Dark Blue	DP
07/01	EVOTEC : RBC reiterates its Buy rating	ZD
06/01	Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million	DJ
05/01	Amgen Inc. acquired Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company and Evotec SE in a transaction valued at $840 million.	CI
02/01	Evotec SE Announces Executive Changes	CI
17/12	Evotec SE Equity Buyback announced on August 6, 2024, has expired.	CI
09/12	Sources: Novo Nordisk Group Holding reduces stake in Evotec	DP
09/12	Evotec secondary ABB priced at EUR 5.10 per share, bookrunner says	RE
09/12	Bookrunner says Evotec secondary ABB books are closed	RE
08/12	Sandoz Concludes Purchase of Evotec's Biologics Platform	MT
08/12	Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership	RE
08/12	Novo Holdings Reportedly Plans to Sell 9.4 Million Shares in Evotec	CI
05/12	Sandoz Group AG completed the acquisition of Just-Evotec Biologics EU SAS from Evotec SE.	CI
04/12	Evotec's Partner Bayer Starts Mid-stage Study of Genetic Kidney Disease Drug	MT
04/12	Bayer Starts Phase IIa Study for Treatment of Patients with Alport Syndrome	CI
04/12	Evotec SE Starts Phase 2 Study for Treatment of Patients with Alport Syndrome	CI
13/11	Sector Update: Health Care Stocks Higher in Afternoon Trading	MT
12/11	Sector Update: Health Care Stocks Mixed Premarket Wednesday	MT
12/11	Sector Update: Health Care	MT

Chart Evotec SE

Duration

Period

EVT: Dynamic Chart

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâ€™s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Employees

4,788

Sector

Biotechnology & Medical Research

Calendar

01/04 - Q4 2025 Earnings Release (Projected)

More about the company